Dr. Leighl's Highlights in Lung Cancer from 2012: MEK Inhibitor Therapy for KRAS Mutation-Positive NSCLC
The next portion of Dr. Leighl's "Highlights of Lung Cancer from 2012" webinar focused on exciting research presented at ASCO 2012 and very recently published on the potential efficacy of a new class of targeted therapy, called MEK inhibitors, for the large subset of patients who have a KRAS mutation.
Dr. David Spigel: What are the most promising targeted therapy approaches in lung cancer for the next few years?
Dr. David Spigel from Sarah Cannon Cancer Center offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.
Here's a recent video podcast I just did on the publication just out in Lancet Oncology, describing a randomized phase II study led by my friend Pasi Janne, from Dana Farber Cancer Institute in Boston.
The report of the phase II randomized trial of MEK inhibitor selumetinib for KRAS mutation-positive NSCLC was just published in Lancet Oncology. Here's my discussion of some of the highlights of this work and what this means.
The annual conference of the American Society of Clinical Oncology in late spring is the biggest event in the cancer world, where more of the big trials are presented than at any other time all year. In the lung cancer world, it’s looking like this one won’t be a blockbuster but will have some promising and interesting findings to dis